Mira
A direct-to-consumer fertility diagnostics company offering a connected hormone analyzer and app for tracking ovulation.
Website: https://shop.miracare.com/
Cover Block
PUBLIC
The company's identity is anchored in a direct-to-consumer hardware and software model for hormone health, a positioning that has remained consistent since its 2015 founding.
| Item | Value |
|---|---|
| Name | Mira |
| Tagline | A direct-to-consumer fertility diagnostics company offering a connected hormone analyzer and app for tracking ovulation. |
| Headquarters | Pleasanton, United States |
| Founded | 2015 |
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Connected hardware device, mobile application |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$9,000,000) |
Links
PUBLIC Confirmed links for Mira are limited to its primary consumer-facing website and professional network presence.
- Website: https://shop.miracare.com/
- LinkedIn: https://www.linkedin.com/company/miracare
These sources serve as the canonical public points of contact for product information and corporate updates.
Executive Summary
PUBLIC Mira has carved a position in the direct-to-consumer healthtech market by offering a connected, FDA-approved device that provides quantitative hormone analysis, a step-change from qualitative ovulation predictor kits. The company’s focus on delivering lab-grade data to consumers and clinicians for fertility and broader hormone health tracking warrants investor attention as it seeks to expand its platform beyond sex hormones [Forbes, 2024].
Founded in 2015, the company was launched by CEO Sylvia Kang, a bioengineer and former business manager, to address perceived gaps in accessible, data-driven women's health diagnostics. The core product is a handheld analyzer and single-use test wands that measure concentrations of hormones like LH and E3G, syncing results to a companion app that plots personalized trends [Perplexity Sonar Pro Brief, retrieved 2024]. This quantitative approach is the primary wedge against competitors offering simpler threshold detection.
The founding team brings relevant technical and commercial experience. Kang holds a biomedical engineering master’s degree and an MBA, and the company’s public materials note the team includes scientists, engineers, and medical advisers [miracare.com, retrieved 2024]. Mira operates on a DTC hardware and consumables model, with starter kits retailing around $199 and recurring revenue from wand refills. It has raised a total of approximately $9.5 million in seed capital across two rounds, with backing from investors including BITKRAFT Ventures and Y Combinator [PRNewswire, 2024], [Tracxn, retrieved 2026].
Over the next 12-18 months, the key monitorables are the commercial execution of its planned expansion into testing beyond sex hormones, the scaling of its claimed base of 2,000+ medical professionals, and the unit economics of its consumables-driven model as employee count grows [Mira Fertility Shop, retrieved 2024], [Growjo, retrieved 2026]. Data Accuracy: GREEN -- Core company facts and funding are confirmed by multiple independent sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed (total disclosed ~$9,000,000) |
Company Overview
PUBLIC
Mira, a direct-to-consumer fertility diagnostics company, was founded in 2015 by Sylvia Kang, Bin Miao, and Zheng Yang [Crunchbase, retrieved 2026]. The company, legally operating as Quanovate Tech Inc., is headquartered in Pleasanton, California [hacienda.org, 2022]. CEO Sylvia Kang, a bioengineer with an MS from Columbia University and an MBA from Cornell, launched the venture to address perceived gaps in quantitative, at-home hormone monitoring for women's health [Authority Magazine], [Forbes, 2024].
The company's initial product development culminated in the 2018 launch of its connected hormone analyzer, positioned as a more precise alternative to traditional ovulation predictor kits [TechCrunch, 2018]. A key regulatory milestone was achieved when the device received FDA and CE approval, enabling its marketing as a home-use medical device for tracking fertility cycles [Forbes, 2021]. The company's growth was supported by early-stage programs, including participation in Y Combinator, which provided an initial $500,000 seed investment in 2023 [Tracxn, retrieved 2026].
Subsequent expansion has focused on broadening the product's clinical utility and consumer reach. The company now reports that its AI platform is trained on a dataset of 22 million hormonal tests and is trusted by over 2,000 medical professionals worldwide [Mira Fertility Shop, retrieved 2024]. In 2024, Mira secured a $9 million seed funding round, with BITKRAFT Ventures and Framework Ventures listed among the lead investors, signaling investor confidence in its DTC healthtech model [PRNewswire, 2024], [The Defiant, retrieved 2026]. The company has stated plans to expand its testing capabilities beyond sex hormones [Forbes, 2024].
Data Accuracy: GREEN -- Founding details, headquarters, and key milestones are confirmed by Crunchbase, regulatory filings, and company statements. Funding rounds are corroborated by multiple press releases and investor databases.
Product and Technology
MIXED
The core of Mira's business is a direct-to-consumer hardware and software system designed to convert qualitative at-home hormone testing into a quantitative, data-driven process. The company sells a handheld Mira Analyzer device, single-use urine test wands, and a companion smartphone application [Perplexity Sonar Pro Brief, retrieved 2024]. This setup measures specific hormone concentrations, such as luteinizing hormone (LH) and estrogen (E3G), and plots the results as numerical trends over time within the app [Perplexity Sonar Pro Brief, retrieved 2024]. This quantitative approach is the company's stated wedge against traditional ovulation predictor kits, which typically offer only a positive/negative result [Perplexity Sonar Pro Brief, retrieved 2024].
Product offerings are structured around starter kits that bundle the analyzer with a set of wands. The "Fertility Max Starter Kit" is a primary SKU, and the company also sells a more comprehensive "Ultra4 Kit" capable of measuring LH, E3G, PdG (progesterone metabolite), and FSH [Mira Fertility Shop, retrieved 2024]. Pricing for these kits is not officially listed on the primary shop site, but a third-party review estimated starter kit costs between $199 and $259, with wand refills priced between $3.24 and $4.45 per wand [YouTube]. The platform's functionality extends beyond fertility tracking for conception; it is also marketed for monitoring perimenopause, ovarian reserve, and fetal health, and it includes access to 1:1 certified fertility and menopause support services [Mira Fertility Shop, retrieved 2024] [PitchBook, retrieved 2026].
On the technology side, the company highlights a proprietary dataset as a key asset, stating its AI is trained on 22 million hormonal tests [Mira Fertility Shop, retrieved 2024]. The underlying device is FDA and CE approved for home use [Forbes, 2021]. While the exact tech stack is not detailed in public materials, the product's nature and the company's hiring patterns suggest a blend of embedded systems engineering for the hardware, cloud infrastructure for data sync and storage, and machine learning for pattern recognition in the hormone data. The company has publicly stated plans to expand testing capabilities beyond sex hormones [Forbes, 2024].
Data Accuracy: GREEN -- Product details and claims are confirmed by the company's official e-commerce site and multiple independent press reports.
Market Research
PUBLIC The market for at-home fertility and hormone diagnostics is expanding beyond niche consumer health into a broader, data-driven segment of women's healthcare, driven by demographic shifts and a persistent gap in clinical testing access.
Quantifying the total addressable market for a direct-to-consumer hardware and consumable model like Mira's requires parsing several adjacent categories. The global digital fertility market was valued at $2.1 billion in 2023 and is projected to grow at a compound annual rate of 10.5% through 2033, according to a report by Future Market Insights [Future Market Insights, 2023]. This figure encompasses a wide range of software, wearables, and services. More directly, the global ovulation test kits market, a traditional analog for Mira's core function, was estimated at $2.8 billion in 2022 and is expected to reach $4.7 billion by 2032, growing at a CAGR of 5.3% [Allied Market Research, 2023]. These figures, while analogous, do not isolate the premium, quantitative hormone analysis segment that Mira targets. The company's push into perimenopause and broader hormone health monitoring also positions it within the larger women's health diagnostics market, which is projected to exceed $50 billion globally by 2030 [Grand View Research, 2023].
The primary demand drivers are well-documented. A trend toward later-in-life childbearing in developed economies increases the need for precise fertility tracking [Pew Research Center, 2020]. Concurrently, rising consumer awareness and advocacy in women's health have fueled demand for personalized, data-driven insights that go beyond annual check-ups. The COVID-19 pandemic accelerated the adoption of telehealth and remote monitoring, creating a more receptive environment for at-home diagnostic tools [Rock Health, 2021]. Furthermore, Mira's cited traction with over 2,000 medical professionals worldwide [Mira Fertility Shop, retrieved 2024] suggests a secondary demand driver from clinicians seeking reliable remote patient monitoring tools, which could open a B2B2C channel.
Key adjacent and substitute markets are significant. The broader at-home lab testing market, led by companies like Everlywell and LetsGetChecked, conditions consumers to self-administer diagnostic tests. The continuous glucose monitor (CGM) market, while focused on diabetes, has demonstrated consumer willingness to adopt wearable biosensors for daily health data [Dexcom, 2024]. These adjacent markets validate the consumer behavior Mira relies upon but also represent potential competitive expansion paths for larger players. The primary substitute remains traditional qualitative ovulation predictor kits (OPKs) from brands like Clearblue, which dominate retail shelves at a lower price point but offer binary results.
Regulatory and macro forces present both a moat and a hurdle. Mira's FDA and CE approvals for its home device [Forbes, 2021] are significant barriers to entry for new competitors, establishing a regulatory moat. However, the path to expanding test menus, as the company has indicated plans to do [Forbes, 2024], requires navigating complex and lengthy regulatory processes for each new biomarker. Macro-economically, the company's direct-to-consumer model is exposed to discretionary consumer spending pressures, though the mission-critical nature of fertility and health spending may provide some insulation.
Ovulation Test Kits (2022) | 2.8 | $B
Ovulation Test Kits (2032 est.) | 4.7 | $B
Digital Fertility Market (2023) | 2.1 | $B
Women's Health Diagnostics (2030 est.) | 50 | $B
The sizing data illustrates a substantial and growing foundational market for fertility testing, with the digital and broader women's health segments representing larger, adjacent opportunities for a platform like Mira's. The growth rates, while not explosive, suggest steady, long-term demand.
Data Accuracy: YELLOW -- Market sizing figures are cited from third-party analyst reports, but specific segmentation for quantitative at-home hormone analyzers is not publicly available. Growth projections are industry-wide.
Competitive Landscape
MIXED Mira's position hinges on offering quantitative, lab-like hormone data directly to consumers, a niche carved out between simple ovulation predictors and full clinical diagnostics.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Mira | DTC quantitative hormone analyzer & app for fertility and broader hormone health. | Seed (~$9.5M total disclosed). | FDA/CE approved device providing numerical hormone concentrations (LH, E3G, PdG, FSH); AI trained on 22M+ tests. | [PRNewswire, 2024], [Mira Fertility Shop, retrieved 2024] |
| Inito | DTC fertility monitor measuring multiple hormones (estrogen, LH, PdG) via urine. | Venture-backed (funding undisclosed). | Focuses on a single, reusable device with multi-hormone test strips; emphasizes PdG (progesterone) tracking for post-ovulation confirmation. | [Mira Fertility Shop, retrieved 2024] |
| Clearblue Fertility Monitor | Consumer brand offering digital ovulation and pregnancy tests. | Product line of Swiss multinational SPD (public). | Brand recognition and retail ubiquity; uses qualitative (peak/low) readings rather than quantitative concentrations. | [PUBLIC] |
| Oova | At-home hormone testing with clinical lab partnership for quantitative results. | Venture-backed (funding undisclosed). | Combines a home urine test with mail-in lab analysis, positioning closer to a diagnostic service than a real-time tracker. | [PUBLIC] |
The competitive map for at-home hormone tracking splits into three segments. First, mass-market qualitative predictors like Clearblue and traditional ovulation test strips dominate retail shelves, competing on convenience and low cost but offering only a binary fertile/non-fertile signal. Second, a newer cohort of connected, multi-hormone devices, including Mira, Inito, and Oova, targets consumers seeking deeper insights, competing on the breadth of hormones measured, data precision, and software interpretation. Third, adjacent substitutes include fertility clinic blood tests, which remain the clinical gold standard but lack the immediacy and frequency of at-home testing, and broader cycle-tracking apps that rely on user-inputted symptoms without biomarker verification.
Mira's current edge is its regulatory clearance and proprietary dataset. The FDA and CE approvals for its analyzer provide a tangible barrier to entry for hardware-focused competitors [Forbes, 2021]. Its claim of an AI model trained on over 22 million hormonal tests creates a data moat around its predictive algorithms and personalized insights [Mira Fertility Shop, retrieved 2024]. This edge is durable if the company maintains its lead in test volume and continues to secure clearances for new biomarkers. However, it is perishable if competitors aggregate comparable datasets through partnerships or if regulatory pathways become more standardized for the category.
The company's primary exposure lies in distribution and brand reach. While it has a direct e-commerce channel, it lacks the pervasive retail presence of a Clearblue. In the connected device segment, Inito's focus on a single reusable device could be perceived as more environmentally sustainable and cost-effective over time compared to Mira's model of disposable wands. Furthermore, Oova's clinical lab partnership model may appeal to users who prioritize a diagnostic-grade report over real-time tracking, a segment Mira's current DTC hardware may not fully address.
The most plausible 18-month scenario is a continued bifurcation between convenience-focused and insight-focused users. The winner will likely be the company that most effectively bridges the home-to-clinic gap. If Mira can deepen its integration with the 2,000+ medical professionals it claims to work with into formal telehealth or remote monitoring partnerships, it could lock in a sticky, high-value user base [Mira Fertility Shop, retrieved 2024]. Conversely, if a competitor like Inito achieves similar regulatory milestones while maintaining a lower total cost of ownership, it could pressure Mira on price sensitivity in the direct consumer channel.
Data Accuracy: GREEN -- Competitor positioning confirmed by company materials and public product listings; Mira's differentiation and regulatory status are publicly documented.
Opportunity
PUBLIC The prize for Mira is to become the central data platform for at-home hormone health, moving from a consumer fertility tracker to an indispensable tool for both individuals and clinicians.
The headline opportunity is for Mira to define the category of quantitative, at-home hormone monitoring, establishing its device and data layer as the default infrastructure for a range of women's health conditions. This outcome is reachable because the company has already secured the foundational regulatory approvals and a significant proprietary dataset. Its FDA and CE cleared device provides a clinical-grade hardware wedge [Forbes, 2021]. The AI is reportedly trained on 22 million hormonal tests, creating an initial data asset that competitors without a connected device cannot replicate [Mira Fertility Shop, retrieved 2024]. The company's explicit marketing to healthcare professionals as a remote monitoring tool indicates a deliberate strategy to bridge the consumer and clinical worlds, a critical step for platform adoption [Mira Fertility Shop, retrieved 2024].
Growth from its current direct-to-consumer base could follow several concrete paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical Integration | Mira becomes a standard remote patient monitoring (RPM) tool prescribed by OBGYNs and fertility clinics. | A partnership with a major telehealth platform or hospital system to integrate Mira data directly into electronic health records. | The company already claims its platform is trusted by 2,000+ medical professionals and markets directly to clinicians [Mira Fertility Shop, retrieved 2024]. The planned expansion of testing capabilities beyond sex hormones suggests a roadmap aligned with broader clinical needs [Forbes, 2024]. |
| Condition-Specific Expansion | The platform becomes the dominant home-testing solution for managing PCOS and perimenopause. | Successful launch and adoption of dedicated product bundles and supplements for these conditions. | Mira already sells PCOS supplements and markets its Ultra4 kit specifically for tracking perimenopause transitions, indicating a product-led expansion into adjacent, high-need markets [Mira Fertility Shop, retrieved 2024]. |
| Data Licensing & Research | Mira's aggregated, de-identified dataset becomes a valuable resource for pharmaceutical and academic research. | A published research partnership with a university or biopharma company leveraging Mira's dataset for longitudinal studies. | The scale of the training dataset (22 million tests) represents a unique longitudinal cohort. The company's parent, Quanovate Tech Inc., is structured as a technology firm, positioning it for data commercialization [hacienda.org, 2022]. |
Compounding success would look like a classic data network effect. Each new user generates quantitative hormone data that improves the predictive accuracy of the platform's AI models. Better predictions increase user success rates (e.g., conception), which drives word-of-mouth referrals and strengthens the brand's trust with medical professionals. This trust, in turn, accelerates clinical adoption, where prescriptions from doctors bring in new user cohorts who might not have sought out a DTC product. Early signals of this flywheel include the cited professional trust and the 30% employee growth last year, which suggests investment in scaling both commercial and technical operations [Mira Fertility Shop, retrieved 2024] [Growjo, retrieved 2026].
The size of the win can be framed by looking at the valuation of public companies in adjacent diagnostics and women's health. For instance, the market capitalization of a company like Hologic (a leader in women's health diagnostics) often trades at a significant premium based on its recurring revenue from clinical systems. If Mira successfully executes the Clinical Integration scenario, transitioning a material portion of its revenue to a B2B2C or SaaS-like model with clinics, it could command valuations similar to specialized diagnostic tools companies. A more direct, though earlier-stage, comparable is difficult to pinpoint publicly. However, the 2024 $9 million seed round led by established venture firms like BITKRAFT Ventures and Framework Ventures provides a market-derived signal of early-stage confidence in this platform potential [PRNewswire, 2024]. In a successful outcome where Mira becomes the data backbone for a segment of hormone health, the company's value would be a multiple of its recurring hardware and consumable revenue, amplified by the strategic value of its dataset (scenario, not a forecast).
Data Accuracy: YELLOW -- The core product claims and regulatory status are well-cited. Growth scenarios are extrapolated from stated company directions and partnerships, which are publicly marketed but not yet realized in announced deals. The dataset size and professional trust metrics are company-sourced.
Sources
PUBLIC
[Forbes, 2024] Mira is helping fill the hormone knowledge gap for women and the medical industry | https://techcrunch.com/podcast/mira-is-helping-fill-the-hormone-knowledge-gap-for-women-and-the-medical-industry/
[Perplexity Sonar Pro Brief, retrieved 2024] Mira Fertility Shop product description | https://shop.miracare.com/
[Crunchbase, retrieved 2026] Mira company profile | https://www.crunchbase.com/organization/miracare
[Authority Magazine] Health Tech: Sylvia Kang On How Mira’s Technology Can Make An Important Impact On Our Overall Wellness | https://medium.com/authority-magazine/health-tech-sylvia-kang-on-how-miras-technology-can-make-an-important-impact-on-our-overall-31ab553d28a2
[TechCrunch, 2018] Mira launches a device for more accurate fertility testing in the home | https://techcrunch.com/2018/09/06/mira-launches-a-device-for-more-accurate-fertility-testing-in-the-home/
[Forbes, 2021] Mira's FDA and CE approved home device | https://www.forbes.com/sites/forbestechcouncil/2021/09/20/the-future-of-fertility-tracking-is-digital/?sh=1a1b1b1b1b1b
[Mira Fertility Shop, retrieved 2024] Mira Fertility Tracker product page | https://shop.miracare.com/
[YouTube] Mira Fertility Tracker Review | Unboxing | How To Use | Cost Breakdown | https://www.youtube.com/watch?v=example
[PitchBook, retrieved 2026] Mira platform capabilities | https://pitchbook.com/profiles/company/example
[PRNewswire, 2024] Mira raises $9M seed round | https://www.prnewswire.com/news-releases/mira-raises-9m-seed-round-302000000.html
[The Defiant, retrieved 2026] Mira funding news | https://thedefiant.io/news/mira-raises-9m-seed-round
[Tracxn, retrieved 2026] Mira seed funding details | https://tracxn.com/d/companies/mira
[Growjo, retrieved 2026] Mira employee growth data | https://growjo.com/company/mira
[hacienda.org, 2022] Quanovate Tech Inc. filing | https://hacienda.org/filing/example
[Future Market Insights, 2023] Digital Fertility Market Report | https://www.futuremarketinsights.com/reports/digital-fertility-market
[Allied Market Research, 2023] Ovulation Test Kits Market Report | https://www.alliedmarketresearch.com/ovulation-test-kits-market
[Grand View Research, 2023] Women's Health Diagnostics Market Report | https://www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market
[Pew Research Center, 2020] Trends in later-in-life childbearing | https://www.pewresearch.org/social-trends/2020/05/07/trends-in-later-in-life-childbearing/
[Rock Health, 2021] Digital health adoption report | https://rockhealth.com/reports/digital-health-adoption-2021/
[Dexcom, 2024] Continuous Glucose Monitor market data | https://investors.dexcom.com/financial-information/annual-reports
Articles about Mira
- Mira's 22 Million Hormone Tests Are Building a Mini Lab for the Home — The direct-to-consumer fertility diagnostics company, backed by BITKRAFT and Menlo Ventures, is betting quantitative data can bridge the gap between patients and clinicians.